ROMAINVILLE, France--(BUSINESS WIRE)--Parc Biocitech - The genome engineering company Cellectis S.A. (Alternext: ALCLS) today announced its full-year financial results for 2008. The company posted its first profit ever (IFRS) of €133k. The full press release is available by clicking here.
